GSA Capital Partners LLP Makes New Investment in Gossamer Bio, Inc. (NASDAQ:GOSS)

GSA Capital Partners LLP purchased a new stake in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 67,546 shares of the company’s stock, valued at approximately $67,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of GOSS. Sequoia Financial Advisors LLC lifted its holdings in Gossamer Bio by 27.2% in the second quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock valued at $84,000 after acquiring an additional 20,000 shares during the period. SG Americas Securities LLC bought a new stake in shares of Gossamer Bio during the 1st quarter valued at about $34,000. Financial Advocates Investment Management increased its position in shares of Gossamer Bio by 57.5% during the 2nd quarter. Financial Advocates Investment Management now owns 106,850 shares of the company’s stock valued at $96,000 after purchasing an additional 39,000 shares during the last quarter. US Bancorp DE purchased a new stake in shares of Gossamer Bio during the 3rd quarter valued at about $39,000. Finally, Choreo LLC bought a new position in shares of Gossamer Bio in the 2nd quarter worth approximately $46,000. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GOSS has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a research report on Monday, November 11th. Wedbush restated an “outperform” rating and issued a $4.00 price objective on shares of Gossamer Bio in a research note on Tuesday, August 13th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $9.20.

Gossamer Bio Stock Performance

GOSS opened at $0.70 on Tuesday. The company has a 50 day simple moving average of $0.91 and a two-hundred day simple moving average of $0.86. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The firm has a market cap of $158.44 million, a P/E ratio of -2.17 and a beta of 1.96. Gossamer Bio, Inc. has a 1-year low of $0.50 and a 1-year high of $1.60.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. The firm had revenue of $9.48 million for the quarter, compared to analysts’ expectations of $4.52 million. Equities analysts forecast that Gossamer Bio, Inc. will post -0.28 earnings per share for the current fiscal year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.